Then we conducted pan-cancer survival analysis of CDKN2A and we found that the OS, DSS, DFS, PFS time of the CDKN2A altered group are all shorter than unaltered group (Figure 1G, all the four p-value <0.001, log-rank test). The gene discussed is CDKN2A; the disease is cancer.